- Trade Names: Daranide; Keveyis (Taro)
- Indications: Glaucoma (Daranide), primary hyperkalemic or hypokalemic periodic paralysis (Keveyis)
- Class: Carbonic anhydrase inhibitor
- Half-life: 8 minutes
- Clinically important, potentially hazardous interactions with:
Aspirin, Cyclosporine, Diflunisal, Lithium, Metformin, Primidone, Salicylates, Salsalate
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
